Abstract
Abstract(−)‐Cannabidiol (CBD) is a non‐psychoactive compound that has already found many medical applications, from the treatment of epilepsy to other neurological disorders. (−)‐CBD is usually extracted from Cannabis Sativa, but unfortunately, its isolation among many other structurally related cannabinoids can be challenging. This, along with the increased demand for (−)‐CBD, prompted chemists to come up with synthetic strategies that could afford this cannabinoid in good yield and high enantiopurity. Herein, we aim to review the fundamental strategies employed in the stereoselective synthesis of (−)‐cannabidiol, spanning from classic approaches to automated ones, highlighting the challenges encountered in the total synthesis of this cannabinoid.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
